Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives
{{output}}
Acute myeloid leukemia (AML) remains a biologically heterogeneous disease with historically limited targeted therapies and poor outcomes. The development of menin inhibitors represents a promising shift, particularly for patients harboring KMT2A rearrangements... ...
